Susan Cleator

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley et al. · The Lancet · 2020 · 1K citations · Full text

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence

R. Charles Coombes, Karen Page, Raheleh Salari et al. · Clinical Cancer Research · 2019 · 481 citations · Full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

John Bridgewater, S. Pugh, Tom Maishman et al. · The Lancet Oncology · 2020 · 227 citations · Full text

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Nancy U. Lin, Eric P. Winer, Duncan Wheatley et al. · Breast Cancer Research and Treatment · 2012 · 194 citations · Full text